Diagnostic accuracy in an incidence cohort of Parkinson’s disease
Objective: To determine the accuracy of clinical diagnosis and research diagnostic criteria in a population-representative cohort of Parkinson's disease (PD) against a neuropathological gold standard…The COVID-19 Pandemic Impact on Advanced Parkinson’s Disease in the US
Objective: Characterize the risk of seven acute medical events in persons with advanced Parkinson’s disease (PD) using real world data before and within 12 months…Does Macronutrient dietary Intake of patients with Parkinson disease correlates with the cognitive function (MoCA)?
Objective: Analyze the correlation between macronutrient dietary intake and cognitive function of patients with Parkinson’s Disease Background: Several studies have shown that implementing a healthy…Challenges around end-of-life care for people with Parkinson’s disease in Kenya
Objective: To explore how people living with Parkinson’s disease (PwP), and their families, in Kenya negotiate the end of life. Background: Parkinson’s disease (PD) is…Home Health Management of Parkinson’s Disease Deep Brain Stimulation: A Randomized Clinical Trial
Objective: Evaluate the efficacy of home health DBS postoperative management in an effort to reduce travel burden and improve access. Background: The travel required to…Evaluating Engagement of ABBV-0805, an Anti-Alpha-Synuclein Monoclonal Antibody to Physiological and Pathological Forms of Alpha-Synuclein for Phase 2 Dose Selection: A PBPK Modeling and Simulation Approach
Objective: To develop a physiologically based pharmacokinetic/pharmacodynamic (PBPK/PD) model to assist in the dose and dosing regimen selection of ABBV-0805 for Phase 2 studies. Background:…Blindness analyses in STEADY-PD3: a phase III placebo-controlled double-blind randomized trial of Isradipine as a disease modifying agent in early Parkinson Disease
Objective: To describe blindness for treatment allocation in STEADY-PD3 and understand the reasons for perceived treatment allocation. Background: The use of a placebo arm aims…Informing the design of disease modifying trials for Parkinson’s disease – A Delphi study
Objective: To assemble an international, multi-stakeholder Delphi panel to seek consensus on trial methodology for an adaptive trial platform investigating disease modifying therapies (DMTs) in…ABBV-0805, a novel α-synuclein oligomer selective antibody, prolonged lifespan and prevented accumulation of α-synuclein pathology in mouse models of Parkinson’s disease
Objective: We report on the pharmacological characteristics of ABBV-0805 (BAN0805), a monoclonal antibody that exhibits a high selectivity for human α-synuclein oligomers and very low…Efficacy and safety of Levodopa-Carbidopa Intestinal Gel in the treatment of Parkinson’s Disease
Objective: Our study aims to analyze the efficacy and safety of Levodopa-carbidopa intestinal gel (LCIG) in Parkinson's disease (PD). Background: Oral Levodopa is considered to…
- « Previous Page
- 1
- …
- 376
- 377
- 378
- 379
- 380
- …
- 436
- Next Page »